Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27791662 | 0.83 | ERCC1 (0.46) | FFAR1ALDH1A1GAAFFAR4ERCC1 | |
| SCHEMBL23166625 | 0.83 | L3MBTL1 (0.61) | ALDH1A1L3MBTL1CYP2C19LMNAKDM4E | |
| SCHEMBL23166009 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNAPKMKDM4EMEN1 | |
| SCHEMBL19720271 | 0.81 | L3MBTL1 (0.47) | FFAR1ALDH1A1GAAL3MBTL1CYP2C19 | |
| SCHEMBL1330698 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 | |
| Hydrochloric Acid SCHEMBL3069393 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 | |
| SCHEMBL41828 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 | |
| Benzene SCHEMBL27714747 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 | |
| SCHEMBL7785939 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 | |
| Hydrochloric Acid SCHEMBL2006870 | 0.81 | ABAT (0.53) | FFAR1ALDH1A1GAAL3MBTL1ERCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| CN-114466844-B | N- (1H-imidazol-2-yl) benzamide compound and pharmaceutical composition comprising same as active ingredient | 康佳诺医疗科技发展有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2022-11-03 | — | — | US | disclosed |
| EP-4038062-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | Kainos Medicine, Inc. (KR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114466844-A | N- (1H-imidazol-2-yl) benzamide compounds and pharmaceutical compositions containing the same as active ingredient | 康佳诺医疗科技发展有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2021066559-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | KAINOS MEDICINE, INC. (KR) | 2021-04-08 | — | — | WO | disclosed |
| EP-1402037-A1 | PLANT GENES INVOLVED IN DEFENSE AGAINST PATHOGENS | Syngenta Participations AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003000898-A1 | PLANT GENES INVOLVED IN DEFENSE AGAINST PATHOGENS | SYNGENTA PARTICIPATIONS AG (CH) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001082697-A2 | SEED TREATMENT COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348560-A1 | N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | IRAK4, IRAK1, IRAK2 | FFAR1 312/4885ALDH1A1 1606/4885GAA 1722/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | FFAR1 442/4885ALDH1A1 2758/4885GAA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.